Hepatocellular carcinoma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Re-evaluation of safety: (1) Those who are diagnosed as malignant tumor by histological or cytological examination; (2) Received Sintilizumab injection treatment during this hospitalization. 2. Economic evaluation: (1) Patients with advanced HCC diagnosed as advanced or intolerant after receiving Sorafenib treatment and/or oxaliplatin-containing chemotherapy; (2) Received Sintilizumab injection or Carrelizumab for injection during the hospital stay.
Exclusion criteria
Exclusion criteria: 1. Re-evaluation of safety: (1) Subjects have poor compliance, which affects safety evaluators; (2) Those who have special physiological changes and are not suitable to continue the experiment; (3) Refuse to sign the informed consent form; (4) Those who have incomplete data and affect safety judgment will not be included in the final data analysis. 2. Economic evaluation: (1) Those whose subjects have poor compliance, which affects safety and efficacy evaluation; (2) Those who have special physiological changes and are not suitable to continue the experiment; (3) Refuse to sign the informed consent form; (4) Those with incomplete data that affect the judgment of safety and efficacy will not be included in the final data analysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse reactions/events;Clinical manifestations of adverse reactions/events;Severity of adverse reactions/events;Outcome of adverse reactions/events;Objective remission rate;Direct medical cost; | — |
Secondary
| Measure | Time frame |
|---|---|
| Risk factors of adverse reactions;Time to response;Duration of response;Progression-free survival;Quality of life (KPS score or ECoG score); | — |
Countries
China
Contacts
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology